2024
Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease
McMillan C, Li D, Mohamed G, Alsadoun D, Almohsen L, Gaidos J, Proctor D, Al-Bawardy B. Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae020. PMID: 38585555, PMCID: PMC10998460, DOI: 10.1093/crocol/otae020.Peer-Reviewed Original ResearchColonoscopy withdrawal timeHigh-definition white light colonoscopyInflammatory bowel diseaseWhite light colonoscopyVisible dysplasiaBowel diseasePersonal historyWithdrawal timeAssociated with detectionEndoscopic healingAdenoma detectionDysplasia detectionDysplasia groupRetrospective studyAdult patientsInvisible dysplasiaColonoscopyPrimary outcomeDysplasiaMultivariate analysisPatientsIncreasing ageGeneral populationMinutesDiseaseImpact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNo therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroids
2023
S1006 Comparison of Upadacitinib Induction in Tofacitinib Exposed and Naïve Patients With Inflammatory Bowel Disease: A Real World Multi-Center Study
Almomen H, Alomar I, McMillan C, Gaidos J, Proctor D, AlMutairdi A, Al-Bawardy B. S1006 Comparison of Upadacitinib Induction in Tofacitinib Exposed and Naïve Patients With Inflammatory Bowel Disease: A Real World Multi-Center Study. The American Journal Of Gastroenterology 2023, 118: s761-s762. DOI: 10.14309/01.ajg.0000953664.83573.de.Peer-Reviewed Original ResearchS947 Why IBD Patients Aren’t Eating ‘an Apple a Day:’ Understanding Dietary Fiber Avoidance in Inflammatory Bowel Disease
Vasudevan J, Damianos J, DiVincenzo C, Gaidos J, Burgermaster M, Feagins L. S947 Why IBD Patients Aren’t Eating ‘an Apple a Day:’ Understanding Dietary Fiber Avoidance in Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2023, 118: s710-s711. DOI: 10.14309/01.ajg.0000953428.77556.69.Peer-Reviewed Original ResearchS1007 No Impact of Primary Language on Treatment and Outcomes for Patients With Inflammatory Bowel Disease in 2 Academic Medical Centers
Chavez V, Vasudevan J, Ochi M, Sahyoun L, Kogan L, Anand T, Gaidos J, Feagins L. S1007 No Impact of Primary Language on Treatment and Outcomes for Patients With Inflammatory Bowel Disease in 2 Academic Medical Centers. The American Journal Of Gastroenterology 2023, 118: s762-s763. DOI: 10.14309/01.ajg.0000953668.62572.df.Peer-Reviewed Original ResearchOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2022
A Practical Approach to IBD Care in the Pregnant Patient
Sahyoun L, Gaidos J. A Practical Approach to IBD Care in the Pregnant Patient. Current Gastroenterology Reports 2022, 24: 201-209. PMID: 36422770, DOI: 10.1007/s11894-022-00856-3.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseManagement of IBDPrior inflammatory bowel diseaseNew IBD therapiesNew biologic agentsPouch-anal anastomosisSimilar success ratesPurpose of ReviewAsIBD careIBD patientsIBD therapyActive diseaseDisease remissionFetal outcomesIBD treatmentPregnant patientsIBD populationPreconception counselingPregnancy outcomesBiologic agentsBowel diseasePeripartum periodMedication safetyPrevious guidelinesPregnancyS883 Impact of Fatigue on Work Productivity and Activity Impairment and Health Care Utilization in Patients With Inflammatory Bowel Disease
Feagins L, Moore P, Crabtree M, Lemay C, Loughlin A, Gaidos J. S883 Impact of Fatigue on Work Productivity and Activity Impairment and Health Care Utilization in Patients With Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2022, 117: e639-e640. DOI: 10.14309/01.ajg.0000860172.94404.2d.Peer-Reviewed Original ResearchImpact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
Nawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.Peer-Reviewed Original ResearchInflammatory bowel diseaseC-reactive proteinAnti-TNF combination therapySteroid-free clinical remissionCombination therapyThiopurine doseDose groupEndoscopic healingClinical remissionBowel diseaseUlcerative colitisCrohn's diseaseTherapeutic doseNormal serum C-reactive proteinAnti-tumor necrosis factorNormal C-reactive proteinSerum C-reactive proteinAnti-drug antibody formationAnti-TNF immunogenicityCohort of patientsLow-dose groupSignificant differencesSecondary outcomesPrimary outcomeClinical outcomes
2021
THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS
Li M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS. Gastroenterology 2021, 160: s62. DOI: 10.1053/j.gastro.2021.01.159.Peer-Reviewed Original ResearchTHE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS
Li M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS. Inflammatory Bowel Diseases 2021, 27: s45-s46. DOI: 10.1093/ibd/izaa347.110.Peer-Reviewed Original ResearchInflammatory bowel diseaseBiologic agentsAdverse eventsSmall molecule therapiesClinical remissionMucosal healingBowel diseaseConcomitant cirrhosisConcomitant corticosteroid therapyDifferent biologic agentsPrimary sclerosing cholangitisQuarter of patientsCohort of patientsEffectiveness of biologicsSmall molecule agentsConcomitant thiopurinesCorticosteroid therapyIBD patientsIBD therapyCertolizumab pegolSclerosing cholangitisAdult patientsBiologic therapyInfusion reactionsSecondary outcomes
2020
Identifying IBD Providers’ Knowledge Gaps Using a Prospective Web-based Survey
Malter L, Jain A, Cohen BL, Gaidos JKJ, Axisa L, Butterfield L, Rescola BJ, Sarode S, Ehrlich O, Cheifetz AS. Identifying IBD Providers’ Knowledge Gaps Using a Prospective Web-based Survey. Inflammatory Bowel Diseases 2020, 26: 1445-1450. PMID: 32100018, DOI: 10.1093/ibd/izaa032.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseAdvanced practice providersPractice providersManagement of patientsProspective web-based surveyMajority of providersMental health providersAdvance practice providersUse of biosimilarsGreatest educational needsMedical education hoursIBD knowledgeIBD providersIBD patientsMD/DODrug holidayElderly patientsPregnant patientsPrior malignancyAdult patientsBowel diseaseTreatment landscapePain managementColitis FoundationTherapy decisionsHigh Prevalence of Male Sexual Dysfunction in a Prospective Multicenter VA Inflammatory Bowel Disease Population
Gaidos J, Naik K, Dave J, Yao M, Hou J, Cipher D, Smith A, Feagins L. High Prevalence of Male Sexual Dysfunction in a Prospective Multicenter VA Inflammatory Bowel Disease Population. Crohn's & Colitis 360 2020, 2: otaa004. PMID: 36777954, PMCID: PMC9801960, DOI: 10.1093/crocol/otaa004.Peer-Reviewed Original ResearchQuality of lifePoor QOLInflammatory bowel diseaseSexual dysfunctionErectile dysfunctionInflammatory bowel disease populationMean age 50 yearsSevere erectile dysfunctionAge 50 yearsMale sexual dysfunctionIBD historySexual desireBiologic useBowel diseaseRisk factorsHigh prevalenceDisease populationMale veteransDysfunctionFunction surveyPrevalenceHypertensionDisease
2019
The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease
Thakur ER, Sansgiry S, Kramer JR, Waljee AK, Gaidos JK, Feagins LA, Govani SM, Dindo L, El-Serag HB, Hou JK. The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019, 26: 1423-1428. PMID: 31728520, PMCID: PMC7441098, DOI: 10.1093/ibd/izz280.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseasePrevalence of anxietyPosttraumatic stress disorderMental health problemsStress disorderBowel diseaseUS veteransIncidence rateChronicity of IBDHealth problemsAnnual incidence rateStress disorder diagnosisPosttraumatic stress disorder (PTSD) diagnosisPost-traumatic stress disorderPresence of anxietyIBD patientsStudy cohortNational cohortAnnual prevalenceDiagnosis incidenceDirect standardization methodGeneral populationPatientsPrior anxietyPrevalenceRates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy
Feagins LA, Kim J, Chandrakumaran A, Gandle C, Naik KH, Cipher DJ, Hou JK, Yao MD, Gaidos JKJ. Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy. Inflammatory Bowel Diseases 2019, 26: 728-733. PMID: 31412114, DOI: 10.1093/ibd/izz175.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseFlare of IBDProstate cancerIBD patientsRadiation treatmentCancer diagnosisRadiation therapyRates of IBDInflammatory bowel disease flaresMultiple logistic regression analysisConcomitant prostate cancerVeterans Affairs hospital systemCharlson Comorbidity IndexRetrospective cohort studyRadiation-treated patientsExternal beam radiationBest treatment approachProstate cancer stageLogistic regression analysisProstate cancer diagnosisDisease flareIBD characteristicsComorbidity indexCohort studyBowel diseaseSa1782 – Effect of Vaccination and Immunosuppressive Medications on Invasive Pneumococcal Disease Occurrence in Veterans with Inflammatory Bowel Disease
Love B, Finney C, Gaidos J. Sa1782 – Effect of Vaccination and Immunosuppressive Medications on Invasive Pneumococcal Disease Occurrence in Veterans with Inflammatory Bowel Disease. Gastroenterology 2019, 156: s-400. DOI: 10.1016/s0016-5085(19)37849-7.Peer-Reviewed Original Research
2018
Health Maintenance Documentation Improves for Veterans with IBD Using a Template in the Computerized Patient Record System
Valluru N, Kang L, Gaidos JKJ. Health Maintenance Documentation Improves for Veterans with IBD Using a Template in the Computerized Patient Record System. Digestive Diseases And Sciences 2018, 63: 1782-1786. PMID: 29736836, DOI: 10.1007/s10620-018-5093-5.Peer-Reviewed Original ResearchConceptsPreventive care measuresComputerized patient record systemCare measuresIBD patientsMedication usePreventive carePatient record systemBackgroundInflammatory bowel diseaseImmunosuppressive medication useRetrospective chart reviewRecord systemHPV vaccinationIBD careChart reviewIBD populationBowel diseasePreventable complicationsProvider documentationClinic notesPhysician performance measuresAimThe aimProvider compliancePatientsDemographic dataMcNemar test
2017
Biologics in Pregnancy and Breastfeeding
Gaidos J, Kane S. Biologics in Pregnancy and Breastfeeding. 2017, 81-99. DOI: 10.1007/978-3-319-60276-9_6.Peer-Reviewed Original ResearchInflammatory bowel diseaseBowel diseaseAnti-IL-12/ILAnti-TNFα inhibitorsAdverse pregnancy outcomesImportance of adherenceAppropriate medical treatmentTime of conceptionActive diseaseDisease remissionNeonatal outcomesPregnancy complicationsPreconception counselingPregnancy outcomesBiologic medicationsLifelong treatmentMedical treatmentPregnancyThird decadeDiseaseRecent evidenceRemissionBreastfeedingMedicationsOutcomesSexuality, Fertility, and Pregnancy in Crohn's Disease
Gaidos J, Kane S. Sexuality, Fertility, and Pregnancy in Crohn's Disease. Gastroenterology Clinics Of North America 2017, 46: 531-546. PMID: 28838413, DOI: 10.1016/j.gtc.2017.05.007.Peer-Reviewed Original ResearchMeSH KeywordsCongenital AbnormalitiesCrohn DiseaseFemaleFertilityHumansImmunosuppressive AgentsInfant, Low Birth WeightInfant, Small for Gestational AgeInfertility, FemaleInfertility, MaleMaleMethotrexatePregnancyPregnancy ComplicationsPremature BirthRisk FactorsSexual HealthStillbirthTumor Necrosis Factor-alphaConceptsCrohn's diseaseAnti-tumor necrosis factor medicationsAdverse pregnancy outcomesInflammatory bowel diseaseActive diseaseQuiescent diseaseMedication regimenPregnancy outcomesBowel diseaseIntrauterine exposureGeneral populationLive vaccineSexual healthDrug concentrationsDiseasePregnancyMonthsOutcomesFertility rateRemissionMedicationsRegimenPatientsInfantsVaccineIncidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease
Feagins LA, Waljee A, Hou JK, Gu P, Kanjo S, Rudrapatna V, Cipher DJ, Govani S, Gaidos J. Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017, 23: 1434-1439. PMID: 28570429, DOI: 10.1097/mib.0000000000001145.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseBiological therapyAdverse drug reactionsConcomitant thiopurinesPrimary nonresponseEarly discontinuationBowel diseaseDrug reactionsDiagnosis of IBDBiological agentsFirst biological agentRetrospective cohort studyInitiation of therapyCourse of therapyVA hospital systemIleocolonic diseaseVA cohortCohort studyVeteran patientsMedical recordsRisk factorsCommon reasonPatientsDiscontinuationTherapy